Guilford, CT, United States of America

Jan Wf Wasley

This inventor holds 1 USPTO granted patent. Top assignee: Neurogen Corporation. Active years: 2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jan Wf Wasley. Retrieved from https://idiyas.com/inventor/jan-wf-wasley-o28mf5f2

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jan Wf Wasley: Innovator in Pharmaceutical Chemistry

Introduction

Jan Wf Wasley is a notable inventor based in Guilford, CT (US). She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of new compounds that have potential therapeutic applications.

Latest Patents

Jan Wf Wasley holds a patent for 1-(N-(arylalkylaminoalkyl) aminoisoquinolines, which represents a new class of dopamine. This patent discloses compounds of a specific formula, including pharmaceutically acceptable salts, where the 6-membered A ring may be optionally substituted with various groups such as halogen, hydroxy, lower alkyl, or lower alkoxy. She has 1 patent to her name.

Career Highlights

Jan Wf Wasley is associated with Neurogen Corporation, where she has been instrumental in advancing research and development in the pharmaceutical sector. Her work focuses on innovative solutions that address complex medical challenges.

Collaborations

Throughout her career, Jan has collaborated with esteemed colleagues, including Xiao-shu He and Brian De Costa. These partnerships have fostered a collaborative environment that enhances the research output and innovation at Neurogen Corporation.

Conclusion

Jan Wf Wasley is a pioneering inventor whose work in pharmaceutical chemistry continues to impact the field significantly. Her contributions, particularly in the development of new dopamine compounds, highlight her role as a key innovator in the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…